|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UQCR11 |
Gene summary for UQCR11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UQCR11 | Gene ID | 10975 |
| Gene name | ubiquinol-cytochrome c reductase, complex III subunit XI | |
| Gene Alias | 0710008D09Rik | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O14957 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10975 | UQCR11 | GSM4909281 | Human | Breast | IDC | 4.22e-04 | 3.13e-01 | 0.21 |
| 10975 | UQCR11 | GSM4909285 | Human | Breast | IDC | 1.30e-15 | -3.36e-01 | 0.21 |
| 10975 | UQCR11 | GSM4909286 | Human | Breast | IDC | 1.88e-04 | 2.02e-01 | 0.1081 |
| 10975 | UQCR11 | GSM4909290 | Human | Breast | IDC | 1.12e-09 | 3.79e-01 | 0.2096 |
| 10975 | UQCR11 | GSM4909291 | Human | Breast | IDC | 1.48e-40 | 6.85e-01 | 0.1753 |
| 10975 | UQCR11 | GSM4909293 | Human | Breast | IDC | 3.60e-02 | -2.59e-02 | 0.1581 |
| 10975 | UQCR11 | GSM4909294 | Human | Breast | IDC | 1.71e-17 | 2.46e-01 | 0.2022 |
| 10975 | UQCR11 | GSM4909296 | Human | Breast | IDC | 4.76e-15 | 2.28e-01 | 0.1524 |
| 10975 | UQCR11 | GSM4909297 | Human | Breast | IDC | 5.04e-20 | 3.38e-02 | 0.1517 |
| 10975 | UQCR11 | GSM4909298 | Human | Breast | IDC | 3.82e-33 | 5.60e-01 | 0.1551 |
| 10975 | UQCR11 | GSM4909301 | Human | Breast | IDC | 1.05e-65 | 7.00e-01 | 0.1577 |
| 10975 | UQCR11 | GSM4909302 | Human | Breast | IDC | 2.45e-17 | 3.64e-01 | 0.1545 |
| 10975 | UQCR11 | GSM4909304 | Human | Breast | IDC | 6.51e-19 | 4.45e-01 | 0.1636 |
| 10975 | UQCR11 | GSM4909306 | Human | Breast | IDC | 1.75e-23 | 5.38e-01 | 0.1564 |
| 10975 | UQCR11 | GSM4909307 | Human | Breast | IDC | 1.80e-08 | 3.29e-01 | 0.1569 |
| 10975 | UQCR11 | GSM4909308 | Human | Breast | IDC | 2.96e-07 | 3.01e-01 | 0.158 |
| 10975 | UQCR11 | GSM4909311 | Human | Breast | IDC | 9.53e-53 | 1.83e-01 | 0.1534 |
| 10975 | UQCR11 | GSM4909312 | Human | Breast | IDC | 8.36e-09 | 1.55e-01 | 0.1552 |
| 10975 | UQCR11 | GSM4909313 | Human | Breast | IDC | 2.12e-07 | 2.33e-01 | 0.0391 |
| 10975 | UQCR11 | GSM4909316 | Human | Breast | IDC | 2.87e-07 | 3.64e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00090601 | Colorectum | SER | aerobic respiration | 96/2897 | 189/18723 | 5.53e-30 | 1.70e-26 | 96 |
| GO:00460341 | Colorectum | SER | ATP metabolic process | 117/2897 | 277/18723 | 5.54e-27 | 1.13e-23 | 117 |
| GO:00453331 | Colorectum | SER | cellular respiration | 103/2897 | 230/18723 | 2.35e-26 | 3.61e-23 | 103 |
| GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
| GO:00061191 | Colorectum | SER | oxidative phosphorylation | 75/2897 | 141/18723 | 2.35e-25 | 2.40e-22 | 75 |
| GO:00159801 | Colorectum | SER | energy derivation by oxidation of organic compounds | 119/2897 | 318/18723 | 5.28e-22 | 4.62e-19 | 119 |
| GO:00229001 | Colorectum | SER | electron transport chain | 77/2897 | 175/18723 | 1.77e-19 | 1.36e-16 | 77 |
| GO:00427731 | Colorectum | SER | ATP synthesis coupled electron transport | 51/2897 | 95/18723 | 6.48e-18 | 3.98e-15 | 51 |
| GO:00427751 | Colorectum | SER | mitochondrial ATP synthesis coupled electron transport | 51/2897 | 95/18723 | 6.48e-18 | 3.98e-15 | 51 |
| GO:00196461 | Colorectum | SER | aerobic electron transport chain | 48/2897 | 87/18723 | 1.37e-17 | 7.63e-15 | 48 |
| GO:00229041 | Colorectum | SER | respiratory electron transport chain | 56/2897 | 114/18723 | 3.34e-17 | 1.71e-14 | 56 |
| GO:00061221 | Colorectum | SER | mitochondrial electron transport, ubiquinol to cytochrome c | 8/2897 | 11/18723 | 3.46e-05 | 9.06e-04 | 8 |
| GO:00090602 | Colorectum | MSS | aerobic respiration | 98/3467 | 189/18723 | 3.35e-25 | 1.05e-21 | 98 |
| GO:00060912 | Colorectum | MSS | generation of precursor metabolites and energy | 186/3467 | 490/18723 | 1.14e-24 | 2.15e-21 | 186 |
| GO:00460342 | Colorectum | MSS | ATP metabolic process | 125/3467 | 277/18723 | 1.38e-24 | 2.15e-21 | 125 |
| GO:00453332 | Colorectum | MSS | cellular respiration | 107/3467 | 230/18723 | 1.64e-22 | 2.05e-19 | 107 |
| GO:00159802 | Colorectum | MSS | energy derivation by oxidation of organic compounds | 131/3467 | 318/18723 | 2.60e-21 | 2.70e-18 | 131 |
| GO:00061192 | Colorectum | MSS | oxidative phosphorylation | 76/3467 | 141/18723 | 3.49e-21 | 3.11e-18 | 76 |
| GO:00229002 | Colorectum | MSS | electron transport chain | 83/3467 | 175/18723 | 2.06e-18 | 1.17e-15 | 83 |
| GO:00229042 | Colorectum | MSS | respiratory electron transport chain | 61/3467 | 114/18723 | 4.46e-17 | 1.99e-14 | 61 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0426016 | Breast | Precancer | Cardiac muscle contraction | 22/684 | 87/8465 | 9.72e-07 | 1.62e-05 | 1.24e-05 | 22 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UQCR11 | SNV | Missense_Mutation | c.133N>A | p.Val45Ile | p.V45I | O14957 | protein_coding | tolerated(0.09) | probably_damaging(0.995) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UQCR11 | SNV | Missense_Mutation | novel | c.149N>A | p.Gly50Asp | p.G50D | O14957 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UQCR11 | SNV | Missense_Mutation | novel | c.72G>T | p.Trp24Cys | p.W24C | O14957 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UQCR11 | SNV | Missense_Mutation | c.113G>T | p.Trp38Leu | p.W38L | O14957 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| UQCR11 | SNV | Missense_Mutation | novel | c.103G>A | p.Ala35Thr | p.A35T | O14957 | protein_coding | tolerated(0.31) | benign(0.259) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
| UQCR11 | SNV | Missense_Mutation | rs200996591 | c.109N>A | p.Asp37Asn | p.D37N | O14957 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-85-A4CL-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UQCR11 | SNV | Missense_Mutation | rs750552580 | c.56N>T | p.Pro19Leu | p.P19L | O14957 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-VQ-A8PB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |